Rogier M. Reijmers
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
Journal: Cells
Published: April 02, 2024
Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs.
Journal: Biological chemistry
Published: November 06, 2023
SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Journal: International journal of molecular sciences
Published: October 11, 2023
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
Journal: Journal for immunotherapy of cancer
Published: May 26, 2023
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Journal: Science translational medicine
Published: December 08, 2021
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
Journal: Cancers
Published: September 29, 2021
Development of follicular dendritic cells in lymph nodes depends on retinoic acid-mediated signaling.
Journal: Development (Cambridge, England)
Published: April 14, 2021
Editorial: Proteoglycans and Glycosaminoglycan Modification in Immune Regulation and Inflammation.
Journal: Frontiers in immunology
Published: August 17, 2020
Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 25, 2019
Last Updated: 09/26/2026